These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31149120)

  • 1. CK19 IS A USEFUL MARKER IN DISTINGUISHING FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA FROM BENIGN THYROID LESIONS WITH FOLLICULAR GROWTH PATTERN.
    Noroozinia F; Gheibi A; Ilkhanizadeh B; Abbasi A
    Acta Endocrinol (Buchar); 2016; 12(4):387-391. PubMed ID: 31149120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.
    Cameron BR; Berean KW
    J Otolaryngol; 2003 Oct; 32(5):319-22. PubMed ID: 14974863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.
    Sadiq Q; Sekhri R; Dibaba DT; Zhao Q; Agarwal S
    World J Surg Oncol; 2021 May; 19(1):143. PubMed ID: 33964951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid.
    El Demellawy D; Nasr A; Alowami S
    Diagn Pathol; 2008 Feb; 3():5. PubMed ID: 18254952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma.
    Bose D; Das RN; Chatterjee U; Banerjee U
    Indian J Med Paediatr Oncol; 2012 Apr; 33(2):107-11. PubMed ID: 22988353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution.
    Sahoo S; Hoda SA; Rosai J; DeLellis RA
    Am J Clin Pathol; 2001 Nov; 116(5):696-702. PubMed ID: 11710686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
    Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
    Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
    Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
    Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical diagnosis of papillary thyroid carcinoma.
    Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
    Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
    Abouhashem NS; Talaat SM
    Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility.
    Baloch ZW; Abraham S; Roberts S; LiVolsi VA
    Hum Pathol; 1999 Oct; 30(10):1166-71. PubMed ID: 10534163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of CK 19 in follicular adenoma, well-differentiated tumour of uncertain malignant potential (WDT-UMP) and follicular variant of papillary carcinoma.
    Bukhari U; Sadiq S; Kehar SI
    J Pak Med Assoc; 2009 Jan; 59(1):15-8. PubMed ID: 19213370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic significance of trophoblast cell-surface antigen-2 expression in benign and malignant thyroid lesions.
    Sadullahoğlu C; Sayıner A; Süren D; Yıldırım HT; Nergiz D; Sezer C; Oruç MT
    Indian J Pathol Microbiol; 2019; 62(2):206-210. PubMed ID: 30971541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions.
    Erdogan-Durmus S; Ozcan D; Yarikkaya E; Kurt A; Arslan A
    J Res Med Sci; 2016; 21():49. PubMed ID: 27904595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Clinicopathologic and Radiographic Findings Between TT-UMP, Classical, and Non-Encapsulated Follicular Variants of Papillary Thyroid Carcinomas.
    Baser H; Topaloglu O; Tam AA; Alkan A; Kilicarslan A; Ersoy R; Cakir B
    Endocr Pathol; 2016 Sep; 27(3):233-42. PubMed ID: 27256097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic criteria of well differentiated thyroid tumor of uncertain malignant potential; a histomorphological and immunohistochemical appraisal.
    Yassin Fel-Z
    J Egypt Natl Canc Inst; 2015 Jun; 27(2):59-67. PubMed ID: 25800580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical and morphometrical evaluation of well-differentiated thyroid tumor of uncertain malignant potential.
    Mohamed DA; Shamlola MM
    Indian J Pathol Microbiol; 2019; 62(1):17-23. PubMed ID: 30706854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic significance of apical membranous and cytoplasmic dot-like CD26 expression in encapsulated follicular variant of papillary thyroid carcinoma: a useful marker for capsular invasion.
    Takagi S; Hirokawa M; Nagashima K; Higuchi M; Kadota K; Ishikawa R; Sato M; Miyauchi A; Miyake Y; Haba R
    Endocr J; 2020 Dec; 67(12):1207-1214. PubMed ID: 32879160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
    Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
    Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic utility of CK19 and galectin-3 in differentiating papillary thyroid carcinoma from nonneoplastic lesions of thyroid.
    Prasad PA; Raju K
    J Cancer Res Ther; 2022; 18(3):644-649. PubMed ID: 35900535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.